Phase III trial of modulation of cisplatin/fluorouracil chemotherapy interferon alfa-2b in patients with recurrent or metastatic head and neck cancer

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 1054-1059

  Schrijvers, D ^a   Johnson, J ^a   Jiminez, U ^a   Gore, M ^a   Kosmidis, P ^a   Szpirglas, H ^a   Robbins, K ^a   Oliveira, J ^a   Lewensohn, R ^a   Schuller J ^a   Riviere, A ^a   Arvay, C ^a   Langecker, P ^a   Jacob, H ^a   Cvitkovic, E ^a   Vokes, E ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CISPLATIN; FLUOROURACIL;

ADULT; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FEVER; HEAD AND NECK CANCER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 6844236387     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.1054     Document Type: Article

References (12)

1. Vokes EE, Weichselbaum RR, Lippman S, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
2. Tobias J: Cancer of the head and neck. BMJ 308:962-966, 1994
3. Vokes EE, Athanasiadis I: Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 7:15-29, 1996
4. Clavel M, Vermorken J, Cognetti F, et al: Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 5:521-526, 1994
5. Campbell J, Dorman E, McCormick M, et al: A randomised phase III trial of cisplatinum, methotrexate, cisplatinum + methotrexate, and cisplatinum + 5-fluorouracil in end-stage head and neck cancer. Acta Otolaryngol 103:519-528, 1987
6. The Liverpool Head and Neck Oncology Group: A phase III randomized trial of cisplatinum, methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 61:311-315, 1990
7. Wadler S, Schwartz E: Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: A review. Cancer Res 50:3473-3486, 1990
8. Carmichael J, Fergusson R, Wolf R, et al: Augmentation of cytotoxicity of chemotherapy by human alfa-interferon in human non small cell lung cancer xenografts. Cancer Res 46:4916-4920, 1986
9. Bensmaine M, Azli N, Domenge C, et al: Phase I-II trial of recombinant interferon alpha-2b with cisplatin and 5-fluorouracil in recurrent and/or metastatic carcinoma of the head and neck. Am J Clin Oncol 19:249-254, 1996
10. Peduzzi P, Witters J, Detre K: Analysis as-randomized and the problem of non-adherence: An example from the Veterans Affairs randomized trial of coronary artery bypass surgery. Stat Med 12:1185-1195, 1992
11. Hussain M, Benedetti J, Smith R, et al: Evaluation of 96-hour 5-FU infusion plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. Cancer 76:1233-1237, 1995
12. Darnell J, Kerr I, Stark G: Jak-STAT pathways and transcriptional activation in response to INFs and other extracellular signaling proteins. Science 264:1415-1420, 1994